Hematologic Oncology

Glofitamab combined with CAR T-cell therapy is associated with improved outcomes in relapsed/refractory B-cell lymphoma.

Obe-cel is associated with durable survival outcomes in relapsed/refractory B-ALL, regardless of BOR of CR or CRi.

Rapcabtagene autoleucel exhibited promising response and safety data in relapsed or refractory B-cell acute lymphoblastic leukemia.

Updated data from TRANSCEND FL showed durable efficacy outcomes with liso-cel in relapsed/refractory follicular lymphoma.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has approved nivolumab plus AVD for adult and pediatric patients with previously untreated stage III or IV classical Hodgkin lymphoma.

Dr Vale discusses data from a phase 2 trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Retrospective data showed longer durations of bridging therapy with a BTK inhibitor improved CAR T-cell therapy response in relapsed/refractory DLBCL.

Will the FDA approve bezuclastinib for the treatment of patients with nonadvanced systemic mastocytosis?

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

Venetoclax plus decitabine/cedazuridine after a venetoclax-based RIC regimen was effective and safe in myelodysplastic syndromes or acute myeloid leukemia.

Sonali Smith, MD, discusses CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults.

The FDA indications for tazemetostat in relapsed/refractory follicular lymphoma and epithelioid sarcoma are being voluntarily withdrawn.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

Ashkan Emadi, MD, PhD, discusses how subcutaneous blinatumomab may represent a treatment approach in mixed phenotype acute leukemia.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

Alexandra Rojek, MD, discusses efforts to improve the safety and efficacy of CAR T-cell therapies in lymphoma through ongoing research.

Sonali M. Smith, MD, discusses efforts to translate benefit with CAR T-cell therapy from hematologic malignancies to the solid tumor space.

A WVU Cancer Institute team investigated the efficacy of subcutaneous blinatumomab in treating one of the rarest and most aggressive forms of leukemia.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.